253 related articles for article (PubMed ID: 36030198)
1. Development and validation of a model to predict cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease.
Stevens SR; Segar MW; Pandey A; Lokhnygina Y; Green JB; McGuire DK; Standl E; Peterson ED; Holman RR
Cardiovasc Diabetol; 2022 Aug; 21(1):166. PubMed ID: 36030198
[TBL] [Abstract][Full Text] [Related]
2. Astronaut Cardiovascular Health and Risk Modification (Astro-CHARM) Coronary Calcium Atherosclerotic Cardiovascular Disease Risk Calculator.
Khera A; Budoff MJ; O'Donnell CJ; Ayers CA; Locke J; de Lemos JA; Massaro JM; McClelland RL; Taylor A; Levine BD
Circulation; 2018 Oct; 138(17):1819-1827. PubMed ID: 30354651
[TBL] [Abstract][Full Text] [Related]
3. Validation of the WATCH-DM and TRS-HF
Segar MW; Patel KV; Hellkamp AS; Vaduganathan M; Lokhnygina Y; Green JB; Wan SH; Kolkailah AA; Holman RR; Peterson ED; Kannan V; Willett DL; McGuire DK; Pandey A
J Am Heart Assoc; 2022 Jun; 11(11):e024094. PubMed ID: 35656988
[TBL] [Abstract][Full Text] [Related]
4. Development and Validation of a Risk Prediction Model for Atherosclerotic Cardiovascular Disease in Japanese Adults: The Hisayama Study.
Honda T; Chen S; Hata J; Yoshida D; Hirakawa Y; Furuta Y; Shibata M; Sakata S; Kitazono T; Ninomiya T
J Atheroscler Thromb; 2022 Mar; 29(3):345-361. PubMed ID: 33487620
[TBL] [Abstract][Full Text] [Related]
5. Cluster Analysis of Cardiovascular Phenotypes in Patients With Type 2 Diabetes and Established Atherosclerotic Cardiovascular Disease: A Potential Approach to Precision Medicine.
Sharma A; Zheng Y; Ezekowitz JA; Westerhout CM; Udell JA; Goodman SG; Armstrong PW; Buse JB; Green JB; Josse RG; Kaufman KD; McGuire DK; Ambrosio G; Chuang LM; Lopes RD; Peterson ED; Holman RR
Diabetes Care; 2022 Jan; 45(1):204-212. PubMed ID: 34716214
[TBL] [Abstract][Full Text] [Related]
6. Risk of major adverse cardiovascular events associated with elevated low-density lipoprotein cholesterol in a population with atherosclerotic cardiovascular disease with and without type 2 diabetes: a UK database analysis using the Clinical Practice Research Datalink.
Morgan CL; Durand A; McCormack T; Hughes E; Berni TR; Lahoz R
BMJ Open; 2023 Nov; 13(11):e064541. PubMed ID: 38030254
[TBL] [Abstract][Full Text] [Related]
7. Performance of the UKPDS Outcomes Model 2 for Predicting Death and Cardiovascular Events in Patients with Type 2 Diabetes Mellitus from a German Population-Based Cohort.
Laxy M; Schöning VM; Kurz C; Holle R; Peters A; Meisinger C; Rathmann W; Mühlenbruch K; Kähm K
Pharmacoeconomics; 2019 Dec; 37(12):1485-1494. PubMed ID: 31350720
[TBL] [Abstract][Full Text] [Related]
8. Machine learning derived ECG risk score improves cardiovascular risk assessment in conjunction with coronary artery calcium scoring.
Siva Kumar S; Al-Kindi S; Tashtish N; Rajagopalan V; Fu P; Rajagopalan S; Madabhushi A
Front Cardiovasc Med; 2022; 9():976769. PubMed ID: 36277775
[TBL] [Abstract][Full Text] [Related]
9. Application of a Lifestyle-Based Tool to Estimate Premature Cardiovascular Disease Events in Young Adults: The Coronary Artery Risk Development in Young Adults (CARDIA) Study.
Gooding HC; Ning H; Gillman MW; Shay C; Allen N; Goff DC; Lloyd-Jones D; Chiuve S
JAMA Intern Med; 2017 Sep; 177(9):1354-1360. PubMed ID: 28715555
[TBL] [Abstract][Full Text] [Related]
10. Associations between β-blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease.
Shavadia JS; Zheng Y; Green JB; Armstrong PW; Westerhout CM; McGuire DK; Cornel JH; Holman RR; Peterson ED
Am Heart J; 2019 Dec; 218():92-99. PubMed ID: 31715435
[TBL] [Abstract][Full Text] [Related]
11. SGLT2 Inhibitors: Effect on Myocardial Infarction and Stroke in Type 2 Diabetes.
Mukhopadhyay P; Sanyal D; Chatterjee P; Pandit K; Ghosh S
J Clin Endocrinol Metab; 2023 Jul; 108(8):2134-2140. PubMed ID: 36856812
[TBL] [Abstract][Full Text] [Related]
12. Universal Risk Prediction for Individuals With and Without Atherosclerotic Cardiovascular Disease.
Mok Y; Dardari Z; Sang Y; Hu X; Bancks MP; Mathews L; Hoogeveen RC; Koton S; Blaha MJ; Post WS; Ballantyne CM; Coresh J; Rosamond W; Matsushita K
J Am Coll Cardiol; 2024 Feb; 83(5):562-573. PubMed ID: 38296400
[TBL] [Abstract][Full Text] [Related]
13. Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS.
Nauck MA; McGuire DK; Pieper KS; Lokhnygina Y; Strandberg TE; Riefflin A; Delibasi T; Peterson ED; White HD; Scott R; Holman RR
Cardiovasc Diabetol; 2019 Sep; 18(1):116. PubMed ID: 31481069
[TBL] [Abstract][Full Text] [Related]
14. Prediction of heart failure outcomes in patients with type 2 diabetes mellitus: Validation of the Thrombolysis in Myocardial Infarction Risk Score for Heart Failure in Diabetes (TRS-HF
Elharram M; Ferreira JP; Huynh T; Ni J; Giannetti N; Verma S; Zannad F; Sharma A
Diabetes Obes Metab; 2021 Mar; 23(3):782-790. PubMed ID: 33269511
[TBL] [Abstract][Full Text] [Related]
15. Association of obesity with cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: Insights from TECOS.
Pagidipati NJ; Zheng Y; Green JB; McGuire DK; Mentz RJ; Shah S; Aschner P; Delibasi T; Rodbard HW; Westerhout CM; Holman RR; Peterson ED;
Am Heart J; 2020 Jan; 219():47-57. PubMed ID: 31707324
[TBL] [Abstract][Full Text] [Related]
16. The effect of radial pulse spectrum on the risk of major adverse cardiovascular events in patients with type 2 diabetes.
Chang CW; Liao KM; Chang YT; Wang SH; Chen YC; Wang GC
J Diabetes Complications; 2019 Feb; 33(2):160-164. PubMed ID: 30381150
[TBL] [Abstract][Full Text] [Related]
17. Development and validation of a novel 10-year cardiovascular risk prediction nomogram for the United Arab Emirates national population.
Al-Shamsi S
BMJ Open; 2022 Dec; 12(12):e064502. PubMed ID: 36581433
[TBL] [Abstract][Full Text] [Related]
18. Time-dependent event accumulation in a cardiovascular outcome trial of patients with type 2 diabetes and established atherosclerotic cardiovascular disease.
Bethel MA; Sourij H; Stevens SR; Hannan K; Lokhnygina Y; Adler AI; Peterson ED; Holman RR; Lopes RD
Cardiovasc Diabetol; 2023 Mar; 22(1):72. PubMed ID: 36978066
[TBL] [Abstract][Full Text] [Related]
19. International Validation of the Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention in Post-MI Patients: A Collaborative Analysis of the Chronic Kidney Disease Prognosis Consortium and the Risk Validation Scientific Committee.
Mok Y; Ballew SH; Bash LD; Bhatt DL; Boden WE; Bonaca MP; Carrero JJ; Coresh J; D'Agostino RB; Elley CR; Fowkes FGR; Jee SH; Kovesdy CP; Mahaffey KW; Nadkarni G; Peterson ED; Sang Y; Matsushita K
J Am Heart Assoc; 2018 Jul; 7(14):. PubMed ID: 29982232
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Large-Scale Proteomics for Prediction of Cardiovascular Events.
Helgason H; Eiriksdottir T; Ulfarsson MO; Choudhary A; Lund SH; Ivarsdottir EV; Hjorleifsson Eldjarn G; Einarsson G; Ferkingstad E; Moore KHS; Honarpour N; Liu T; Wang H; Hucko T; Sabatine MS; Morrow DA; Giugliano RP; Ostrowski SR; Pedersen OB; Bundgaard H; Erikstrup C; Arnar DO; Thorgeirsson G; Masson G; Magnusson OT; Saemundsdottir J; Gretarsdottir S; Steinthorsdottir V; Thorleifsson G; Helgadottir A; Sulem P; Thorsteinsdottir U; Holm H; Gudbjartsson D; Stefansson K
JAMA; 2023 Aug; 330(8):725-735. PubMed ID: 37606673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
